|
gptkbp:instanceOf
|
gptkb:drug
small interfering RNA
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N07XX12
|
|
gptkbp:brand
|
gptkb:Onpattro
|
|
gptkbp:CASNumber
|
1395044-51-1
|
|
gptkbp:cost
|
high
|
|
gptkbp:developer
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
lipid nanoparticle
|
|
gptkbp:hasMolecularFormula
|
C528H658N176O316P43S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
patisiran
|
|
gptkbp:indication
|
polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:RNA_interference
|
|
gptkbp:orphanDrug
|
yes
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:reduces
|
transthyretin protein production
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
edema
abdominal pain
flushing
arthralgia
infusion-related reactions
upper respiratory tract infections
|
|
gptkbp:target
|
gptkb:transthyretin_mRNA
|
|
gptkbp:UNII
|
Q9W0P4F2A4
|
|
gptkbp:usedFor
|
hereditary transthyretin-mediated amyloidosis
|
|
gptkbp:bfsParent
|
gptkb:Onpattro
gptkb:hereditary_transthyretin_amyloidosis
gptkb:transthyretin_amyloidosis
|
|
gptkbp:bfsLayer
|
7
|